8-K: Kindly MD Faces Nasdaq Delisting Warning Over Share Price

Kindly MD, Inc. received a notice from Nasdaq regarding non-compliance with the minimum bid price rule, triggering a 180-day period to regain compliance.

Summary

• Kindly MD, Inc. received a notice from The Nasdaq Stock Market LLC on December 10, 2025, indicating non-compliance with Nasdaq Listing Rule 5450(a)(1).
• The non-compliance is due to the company's common stock closing bid price being less than $1.00 per share for 30 consecutive business days.
• The notice does not immediately impact the listing, and the company's common stock continues to trade on the Nasdaq Global Market under the symbol NAKA.
• The company has a 180-calendar-day period, until June 8, 2026, to regain compliance.
• To regain compliance, the common stock's closing bid price must be $1.00 or more for a minimum of 10 consecutive business days.
• If compliance is not regained within the initial period, the company may be eligible for additional time by transferring to the Nasdaq Capital Market, requiring an application and a $5,000 fee.
• Transferring to the Nasdaq Capital Market would require meeting all initial listing standards except the minimum bid price, and providing written notice of intent to cure the deficiency, potentially through a reverse stock split.

Sentiment

Score: 3

Explanation: The company received a delisting notice from Nasdaq due to its stock trading below $1.00, indicating significant share price weakness and regulatory pressure. While a compliance period and options exist, the underlying issue is negative.

Negatives

• The company's common stock has traded below $1.00 for 30 consecutive business days, indicating significant share price weakness.
• Receipt of a delisting notice from Nasdaq creates uncertainty and potential for the stock to be removed from the Nasdaq Global Market.

Risks

• Failure to regain compliance with Nasdaq's minimum bid price rule could lead to the delisting of the company's common stock.
• The company may need to effect a reverse stock split to cure the minimum bid price deficiency, which can be dilutive or negatively perceived by investors.
• There is no assurance that the company will be successful in maintaining its listing on the Nasdaq Global Market or, if transferred, on the Nasdaq Capital Market.

Future Outlook

The company intends to actively monitor its minimum bid price and will consider available options to resolve the deficiencies and regain compliance with Nasdaq Listing Rules, including applying to transfer to the Nasdaq Capital Market or effecting a reverse stock split. However, there is no assurance of success in maintaining its listing.

Management Comments

• "The Company intends to actively monitor its minimum bid price of listed securities and, as appropriate, will consider available options to resolve the deficiencies and regain compliance with the Nasdaq Listing Rules, including applying to transfer to the Nasdaq Capital Market or effecting a reverse stock split."

Industry Context

Receiving a minimum bid price deficiency notice is a common challenge for smaller-cap companies listed on Nasdaq, often reflecting broader market sentiment or specific company performance issues. Many companies face similar situations and must implement strategies like reverse stock splits or market transfers to maintain their listing.

Stakeholder Impact

• Shareholders face the risk of potential delisting from Nasdaq, which could reduce liquidity and investor confidence.
• Shareholders may experience dilution or a change in share structure if a reverse stock split is implemented to regain compliance.

Next Steps

• Monitor the minimum bid price of its listed securities.
• Consider applying to transfer to the Nasdaq Capital Market if compliance is not regained within the initial period.
• Consider effecting a reverse stock split as a potential measure to cure the minimum bid price deficiency.

Key Dates

Recommendation

The company's receipt of a Nasdaq delisting notice due to its common stock trading below $1.00 for 30 consecutive business days signals significant underlying weakness and regulatory risk. While a compliance period is granted, the need to potentially execute a reverse stock split or transfer markets indicates a challenging outlook for shareholder value. Investors should consider selling to mitigate further downside risk associated with potential delisting or dilution from a reverse stock split.

Keywords

Kindly MD, NAKA, Nasdaq, delisting, minimum bid price, compliance, reverse stock split, 8-K